TY - JOUR
T1 - 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
T2 - A consensus and data-driven methodology involving three international patient cohorts
AU - Shiboski, Caroline H.
AU - Shiboski, Stephen C.
AU - Seror, Raphaèle
AU - Criswell, Lindsey A.
AU - Labetoulle, Marc
AU - Lietman, Thomas M.
AU - Rasmussen, Astrid
AU - Scofield, Hal
AU - Vitali, Claudio
AU - Bowman, Simon J
AU - Mariette, Xavier
AU - Kruize, A
AU - Radstake, TRDJ
N1 - Publisher Copyright:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
PY - 2017/11
Y1 - 2017/11
N2 - Objectives To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These criteria were developed for use in individuals with signs and/or symptoms suggestive of SS. Methods We assigned preliminary importance weights to a consensus list of candidate criteria items, using multi-criteria decision analysis. We tested and adapted the resulting draft criteria using existing cohort data on primary SS cases and non-SS controls, with case/noncase status derived from expert clinical judgement. We then validated the performance of the classification criteria in a separate cohort of patients. Results The final classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm2, each scoring 3; an abnormal Ocular Staining Score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer's test result of ≤5 mm/5 min and an unstimulated salivary flow rate of ≤0.1 mL/min, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert-derived case/non-case status in the final validation cohort were high, that is, 96% (95% CI92% to 98%) and 95% (95% CI 92% to 97%), respectively. ConclusionUsing methodology consistent with other recent ACR/EULAR-approved classification criteria, we developed a single set of data-driven consensus classification criteria for primary SS, which performed well in validation analyses and are well suited as criteria for enrolment in clinical trials.
AB - Objectives To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These criteria were developed for use in individuals with signs and/or symptoms suggestive of SS. Methods We assigned preliminary importance weights to a consensus list of candidate criteria items, using multi-criteria decision analysis. We tested and adapted the resulting draft criteria using existing cohort data on primary SS cases and non-SS controls, with case/noncase status derived from expert clinical judgement. We then validated the performance of the classification criteria in a separate cohort of patients. Results The final classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm2, each scoring 3; an abnormal Ocular Staining Score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer's test result of ≤5 mm/5 min and an unstimulated salivary flow rate of ≤0.1 mL/min, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert-derived case/non-case status in the final validation cohort were high, that is, 96% (95% CI92% to 98%) and 95% (95% CI 92% to 97%), respectively. ConclusionUsing methodology consistent with other recent ACR/EULAR-approved classification criteria, we developed a single set of data-driven consensus classification criteria for primary SS, which performed well in validation analyses and are well suited as criteria for enrolment in clinical trials.
KW - Autoantibodies
KW - Autoantigens
KW - Biopsy
KW - Clinical Trials as Topic
KW - Consensus
KW - Humans
KW - Journal Article
KW - Patient Selection
KW - Practice Guidelines as Topic
KW - RNA, Small Cytoplasmic
KW - Ribonucleoproteins
KW - Saliva
KW - Salivary Glands
KW - Sensitivity and Specificity
KW - Sialadenitis
KW - Sjogren's Syndrome
KW - Validation Studies
UR - http://www.scopus.com/inward/record.url?scp=84994494311&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2016-210571
DO - 10.1136/annrheumdis-2016-210571
M3 - Article
C2 - 27789466
AN - SCOPUS:84994494311
SN - 0003-4967
VL - 76
SP - 9
EP - 16
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 1
ER -